Metagenomi Therapeutics EPS - Earnings per Share 2022-2025 | MGX
Metagenomi Therapeutics eps - earnings per share from 2022 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Metagenomi Therapeutics Annual EPS | |
|---|---|
| 2024 | $-2.36 |
| 2023 | $-20.05 |
| 2022 | $-12.82 |
| 2021 | $-6.58 |
| Metagenomi Therapeutics Quarterly EPS | |
|---|---|
| 2025-09-30 | $-0.55 |
| 2025-06-30 | $-0.54 |
| 2025-03-31 | $-0.68 |
| 2024-12-31 | $-0.37 |
| 2024-09-30 | $-0.51 |
| 2024-06-30 | $-0.29 |
| 2024-03-31 | $-1.19 |
| 2023-12-31 | $-5.67 |
| 2023-09-30 | $-5.82 |
| 2023-06-30 | $-3.82 |
| 2023-03-31 | $-4.74 |
| 2022-12-31 | $0.00 |
| 2021-12-31 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.057B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.352B | 12.21 |
| BridgeBio Pharma (BBIO) | United States | $14.131B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.864B | 18.45 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.944B | 24.10 |
| Bausch Health Cos (BHC) | Canada | $2.255B | 1.60 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.314B | 9.47 |
| Taysha Gene Therapies (TSHA) | United States | $1.276B | 0.00 |
| Personalis (PSNL) | United States | $0.790B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.433B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.184B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |